Jason Pontin

General Partner

2023 - Current

Partner

2021 - 2023

DCVC backs brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry.

Board Chair

2023

Kanvas's novel spatial biology plat­form enables an unprece­dent­ed under­stand­ing of host-micro­bio­me inter­ac­tion and pro­vides an effi­cient approach to drug discovery for live biological products.

Board Member

2023

Recycleye sells AI robotics and computer vision technologies for innovative waste and materials management.

Board Member

2023

Aquafortus was founded in New Zealand to develop and commercialize a novel and proprietary zero liquid discharge technology that can treat high salinity wastewater at a fraction of the cost of current processes.

Board Chair

2022

DVLP is building a new infrastructure for drug development on the blockchain. By digitizing drug assets, financing, and development workflows, we are reimagining and accelerating the entire process to turn more molecules into medicines.

Board Member

2022

Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets.

Board Chair

2022

ZwitterCo's zwitterionic membranes can handle unprecedented levels of oil and grease without irreversible fouling, recovering full performance.

Board Chair

2021

A breakthrough technology for continuous health monitoring, more than a decade in development at Helmholtz Institute and Caltech, now in commercial development, which will allow people to be better stewards of their own health.

Board Member

2021

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesize DNA at unprecedented accuracy, scale and speed. The company's platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made, and used—a new paradigm for gene synthesis.

Founding Board Member, Cofounder, and Initial Investor (through Social Impact Capital)

2019

Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.